Pharma Integrates 2023 Track 1

Big Health Issues and Technology

How do we tackle some of the biggest health challenges, such as chronic conditions, respiratory and cancer?

How can we use technology to improve health outcomes, improve sustainability and create robust supply chains?


Welcome and Fireside Chat

Welcome & Opening Remarks

Susan Rienow | Country President UK, Pfizer | President, ABPI

Introduced by:

Trevor Jones CBE | Chairman, e-Therapeutics | Board Member, Respiratory Innovation Wales and Ascension Healthcare

Fireside Chat

Pharma CEO Plenary Discussion: View from the top – navigating the opportunities and challenges presented by a dynamic UK environment and achieving success.

Speakers include:

Susan Rienow | Country President UK, Pfizer | President, ABPI

Marie-Andrée Gamache | Country President | Novartis UK and Ireland

Dr Antonio Payano | Chief Executive Officer | Bayer UK & Ireland

Interviewed by:

Tamsin Berry | Head of Policy and Partnerships, AreteiaTx | Partner, Population Health Partners

Session 1: Panel Discussion followed by Q&A

AI – ‘intelligent’ or simply ‘artificial’?

‘AI, ‘data’, and ‘digital’ are the buzzwords of current innovation. How can we best apply advances in artificial intelligence, data science, and digital technology to bring better treatments to patients?


Phil Carvil | Head of Clusters (NW) | UKRI Science and Technology Facilities Council


Jenny Barnett | Chief Executive Officer | Monument Therapeutics

Joshua Blight | Chief Executive Officer & Co-Founder | Baseimmune

Casper Wilstrup | Chief Executive Officer | Abzu

Jorge Costa | Life Sciences Industry Consultant | Emerson

Jonathan Smith | Co-Founder & Director | Veraxis

Session 2: Panel Discussion followed by Q&A

Can the NHS and pharma work together to solve the burden of long-term diseases?

As life expectancy increases, so does the economic burden of managing chronic diseases. How can we better diagnose, treat, and prevent long-term conditions such as diabetes, cardiovascular disease, and respiratory disease?


Tim Ringrose | Chief Executive Officer | Cognitant


Ian Philp | Founder | Age Care Technologies

Sheuli Porkess | Chief Medical Officer and Business Unit Director | Precisia Life Sciences, a C2-Ai business

Rina Newton | Co-Founder | Code Clarity

Joep Hufman | Country Medical Director UK & Ireland | Bayer Pharma

Stephanie Campbell | Founder & Chief Executive Officer | OKKO Health

Session 3: Panel Discussion followed by Q&A


Partnering – for better or for worse?

CDMOs and CROs have long been well established players on the pharmaceutical scene. As our ways of working continue to evolve, how has partnering changed?


Brennan Miles | Head of Drug Delivery | Team Consulting


Christian Jones | Chief Commercial Officer | Nanoform

David Harrison | Senior Director, Head of Device Manufacturing Partnerships | UCB

Chris Davison | Chief Executive Officer | Custom Pharma Services

Dave Wightman | Director, External Development and Manufacturing | AstraZeneca

James Fry | Partner and Head of Life Sciences | Mills & Reeve

Olivia Boyce | Director of Project Management | SK biotek

Session 4: Panel Discussion & Q&A


Technology – a new link in a broken supply chain?

The Covid pandemic brought a sharp focus on the fragility of supply chains. Has this driven a lasting trend for onshoring manufacturing capabilities and embracing new tech to streamline supply? How are distribution models changing and how quickly are we moving to greener supply chains?


Stefan Kulik | Managing Director | Royal Mail Health


Richard Vellacott | Chief Executive Officer | BiologIC Technologies

Jagjit Singh Srai | Director of Research | University of Cambridge

Manjit Jhooty | Chief Executive Officer | Jhoots Group

Mark Buswell | Vice President, Quality Tech | GSK

Hui Yi Tee | Business Development Manager | Nanoform

Session 5: Panel Discussion & Q&A


Big CDMO, Small CDMO

The CDMO industry is evolving. With the model of the “mega CDMO” emerging, how will this shape the contract manufacturing landscape, and what are the implications for competition among smaller and speciality CDMOs?


Christophe Le Ret | Global Marketing Director | Umicore


Steven Facer | Vice President of Business Development EU/ROW | Adare Pharma Solutions

Martin Doorbar | Chief Development Officer; Non Clinical | Ellipses Pharma

Claire Thompson | Chief Executive Officer | Agility Life Sciences

Giuliano Perfetti | Chief Executive Officer & Managing Director | Jubilant Biosys

Valeria Ciarnelli | Senior Director, Product Development | Quotient Sciences